Hussman Strategic Advisors Inc. Sells 42,000 Shares of ADMA Biologics Inc $ADMA

Hussman Strategic Advisors Inc. decreased its position in shares of ADMA Biologics Inc (NASDAQ:ADMA) by 40.0% during the second quarter, HoldingsChannel reports. The institutional investor owned 63,000 shares of the biotechnology company’s stock after selling 42,000 shares during the period. Hussman Strategic Advisors Inc.’s holdings in ADMA Biologics were worth $1,147,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in ADMA. Intech Investment Management LLC increased its holdings in shares of ADMA Biologics by 164.2% in the 1st quarter. Intech Investment Management LLC now owns 292,595 shares of the biotechnology company’s stock worth $5,805,000 after purchasing an additional 181,839 shares in the last quarter. Strs Ohio bought a new stake in ADMA Biologics in the 1st quarter worth about $1,307,000. Vident Advisory LLC purchased a new position in ADMA Biologics in the 1st quarter worth about $2,735,000. Caxton Associates LLP bought a new position in ADMA Biologics during the 1st quarter valued at about $668,000. Finally, Y Intercept Hong Kong Ltd boosted its holdings in shares of ADMA Biologics by 107.6% during the 2nd quarter. Y Intercept Hong Kong Ltd now owns 74,891 shares of the biotechnology company’s stock valued at $1,364,000 after acquiring an additional 38,809 shares during the last quarter. 75.68% of the stock is owned by institutional investors.

ADMA Biologics Stock Down 4.8%

ADMA stock opened at $14.63 on Wednesday. The company has a market cap of $3.49 billion, a price-to-earnings ratio of 17.01 and a beta of 0.47. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.78 and a current ratio of 5.33. The business’s 50-day moving average is $15.53 and its two-hundred day moving average is $17.97. ADMA Biologics Inc has a fifty-two week low of $13.50 and a fifty-two week high of $25.67.

ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported $0.15 EPS for the quarter, beating the consensus estimate of $0.14 by $0.01. ADMA Biologics had a net margin of 44.06% and a return on equity of 41.01%. The firm had revenue of $121.98 million during the quarter, compared to analyst estimates of $121.77 million. During the same quarter in the prior year, the firm earned $0.13 EPS. The business’s revenue for the quarter was up 13.8% compared to the same quarter last year. As a group, analysts forecast that ADMA Biologics Inc will post 0.51 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings lowered shares of ADMA Biologics from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Friday, October 24th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $27.67.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.